Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Comp Eff Res ; 13(7): e230164, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38869838

ABSTRACT

Background: Eligibility criteria are pivotal in achieving clinical trial success, enabling targeted patient enrollment while ensuring the trial safety. However, overly restrictive criteria hinder enrollment and study result generalizability. Broadening eligibility criteria enhances the trial inclusivity, diversity and enrollment pace. Liu et al. proposed an AI pathfinder method leveraging real-world data to broaden criteria without compromising efficacy and safety outcomes, demonstrating promise in non-small cell lung cancer trials. Aim: To assess the robustness of the methodology, considering diverse qualities of real-world data and to promote its application. Materials/Methods: We revised the AI pathfinder method, applied it to relapsed and refractory multiple myeloma trials and compared it using two real-world data sources. We modified the assessment and considered a bootstrap confidence interval of the AI pathfinder to enhance the decision robustness. Results & conclusion: Our findings confirmed the AI pathfinder's potential in identifying certain eligibility criteria, in other words, prior complications and laboratory tests for relaxation or removal. However, a robust quantitative assessment, accounting for trial variability and real-world data quality, is crucial for confident decision-making and prioritizing safety alongside efficacy.


Subject(s)
Multiple Myeloma , Patient Selection , Humans , Multiple Myeloma/therapy , Multiple Myeloma/drug therapy , Artificial Intelligence , Clinical Trials as Topic/methods , Eligibility Determination/methods
2.
J Biopharm Stat ; 33(6): 726-736, 2023 11 02.
Article in English | MEDLINE | ID: mdl-36524777

ABSTRACT

The use of Bayesian methodology to design and analyze pediatric efficacy trials is one of the possible options to reduce their sample size. This reduction of the sample size results from the use of an informative prior for the parameters of interest. In most of the applications, the principle of 'information borrowing' from adults' trials is applied, which means that the informative prior is constructed using efficacy results in adult of the drug under investigation. This implicitly assumes similarity in efficacy between the selected pediatric dose and the efficacious dose in adults. The goal of this article is to propose a method to construct prior distribution for the parameter of interest, not directly constructed from the efficacy results of the efficacious dose in adult patients but using pharmacodynamic modeling of a bridging biomarker using early phase pediatric data. When combined with a model bridging the biomarker with the clinical endpoints, the prior is constructed using a variational method after simulation of the parameters of interest. A use case application illustrates how the method can be used to construct a realistic informative prior.


Subject(s)
Models, Statistical , Research Design , Adult , Humans , Child , Bayes Theorem , Sample Size , Computer Simulation , Biomarkers
3.
PLoS One ; 17(12): e0278842, 2022.
Article in English | MEDLINE | ID: mdl-36520950

ABSTRACT

Inverse odds of participation weighting (IOPW) has been proposed to transport clinical trial findings to target populations of interest when the distribution of treatment effect modifiers differs between trial and target populations. We set out to apply IOPW to transport results from an observational study to a target population of interest. We demonstrated the feasibility of this idea with a real-world example using a nationwide electronic health record derived de-identified database from Flatiron Health. First, we conducted an observational study that carefully adjusted for confounding to estimate the treatment effect of fulvestrant plus palbociclib relative to letrozole plus palbociclib as a second-line therapy among estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer patients. Second, we transported these findings to the broader cohort of patients who were eligible for a first-line therapy. The interpretation of the findings and validity of such studies, however, rely on the extent that causal inference assumptions are met.


Subject(s)
Breast Neoplasms , Receptor, ErbB-2 , Humans , Female , Receptor, ErbB-2/metabolism , Letrozole/therapeutic use , Receptors, Estrogen/metabolism , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Piperazines/therapeutic use , Pyridines/therapeutic use , Breast Neoplasms/pathology
4.
J Appl Stat ; 49(9): 2370-2388, 2022.
Article in English | MEDLINE | ID: mdl-35755084

ABSTRACT

The formulation of variable selection has been widely developed in the Bayesian literature by linking a random binary indicator to each variable. This Bayesian inference has the advantage of stochastically exploring the set of possible sub-models, whatever their dimension. Bayesian selection approaches, appropriate for categorical predictors, are generally beyond the scope of the standard Bayesian selection of regressors in the linear model since all levels of a categorical variable should be jointly handled in the selection procedure. For categorical covariates, new strategies have been developed to detect the effect of grouped covariates rather than the single effect of a quantitative regressor. In this paper, we review three Bayesian selection methods for categorical predictors: Bayesian Group Lasso with Spike and Slab priors, Bayesian Sparse Group Selection and Bayesian Effect Fusion using model-based clustering. The motivation behind this paper is to provide detailed information about the implementation of the three Bayesian selection methods mentioned above, appropriate for categorical predictors, using the JAGS software. Selection performance and sensitivity analysis of the hyperparameters tuning for prior specifications are assessed under various simulated scenarios. JAGS helps user implement these three Bayesian selection methods for more complex model structures such as hierarchical ones with latent layers.

5.
J Biopharm Stat ; 31(4): 469-489, 2021 07 04.
Article in English | MEDLINE | ID: mdl-34403296

ABSTRACT

The use of real-world data became more and more popular in the pharmaceutical industry. The impact of real-world evidence is now well emphasized by the regulatory authorities. Indeed, the analysis of this type of data can play a key role for treatment efficacy and safety. The aim of this work is to assess various methods and give guidance on the comparisons of drugs, mostly with respect to time-to-event data, in non-randomized studies with potentially confounding variables. For that purpose, several statistical methodologies are compared based on simulation studies. These methodologies belong to family classes of methods that are widely used for this type of problem: regression, matching, weighting and subclassification methods. The evaluation criteria used to compare methods performances are the relative bias, the mean square error, the coverage probability and the width of the confidence interval. In this paper, we consider different scenarios of dataset features in order to study the effect of the sample size, the number of covariates and the magnitude of the treatment effect on the statistical methodologies performances. These statistical analyses are conducted within a proportional hazard model framework. Furthermore, we highlight the advantage of using techniques to identify relevant covariates for time-to-event outcomes by comparing two variable selection methods under a frequentist and a Bayesian inference. Based on simulation results, recommendations on each of the family of methods are provided to guide decision making.


Subject(s)
Bayes Theorem , Bias , Humans , Probability , Proportional Hazards Models , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...